Contributors

Maria Leon-Roux
Bernard Levin
Ni-Li
Patrick Massonneau
James McKay
Koichiro Miki
Gordon McWhir
Richard Milas
Maria-Claudia Navarro
Twesk Njiga
Hiroko Nishigaki
Shigeru Omi
Claudio Pecchioni
Los Pinaos Ashton
Samuel Palmberg
Amilie Plymoth
Qing Qing
Kunnambath Ramadas
Giorgia Randi
Dariusz Ratafia
Alien Rodger
Massoud Samiei
Rong Xue
Mary Jane Schier
Vladimir Semiglazov
Hai-Rim Shin
Sudhir Srivastava
Eva Steliarova-Foucher
Kurt Straif
Bakary Sylla
Sean Tavtigian
Massimo Tommasino
Mariano Barbacid
Patrick Tai
Lionel White
Yuan-Zhang
Ping Zhao
Tongzhang Zheng

For a complete list of contributors and their affiliations see pages 493-496

Contents

Contributors 499
Subject index 503

Contributors

Rosita Accardi
Clement Adabahowo
Ben Anderson
Philippe Aron
Robert Baan
Mariano Barbacid
Paolo Boffetta
Mathieu Boniol
Peter Boyle
Jo Brand
Anne Brédart
Paul Brennan
Jean-Benoît Burrion
Elodie Caboux
Franco Cavalli
Young-eun Cho
Gary Clifford
Vincent Cogliano
Maria-Paula Curado
David Currow
Jean-Marie Dangou
Ketayun Dinshaw
Sylvie Dolbeault
Jean-François Doré
Rayjean J. Hung
Mazda Jenab
Miklos Kasler
David Kerr
Heinrich Kovar
Carlo La Vecchia
Maria Leon-Roux
Bernard Levin
Ni-Li
Patrick Massonneau
James McKay
Koichiro Miki
Gordon McWhir
Richard Milas
Maria-Claudia Navarro
Twesk Njiga
Hiroko Nishigaki
Shigeru Omi
Claudio Pecchioni
Los Pinaos Ashton
Samuel Palmberg
Amilie Plymoth
Qing Qing
Kunnambath Ramadas
Giorgia Randi
Dariusz Ratafia
Alien Rodger
Massoud Samiei
Rong Xue
Mary Jane Schier
Vladimir Semiglazov
Hai-Rim Shin
Sudhir Srivastava
Eva Steliarova-Foucher
Kurt Straif
Bakary Sylla
Sean Tavtigian
Massimo Tommasino
Mariano Barbacid
Patrick Tai
Lionel White
Yuan-Zhang
Ping Zhao
Tongzhang Zheng

Contributors

Foreword 9
1. Global Cancer Control 11
1.1 Introduction: Needs and Prospects for Cancer Control 40
1.2 Cancer Nomenclature 40
1.3 Worldwide Cancer Burden 42
1.4 Cancer Control in low-resource environments 56
1.5 Principles of Cancer Therapy: Medical Oncology 62
1.6 Basics of Cancer Surgery 68
1.7 Radiotherapy 72
1.8 Principles of Supportive and Palliative Care 76
1.9 Psycho-Oncology 82
1.10 Rehabilitation in Oncology 92
1.11 Modern Imaging in Oncology 96
1.12 Breast Health Care delivery in low- and Middle-Income Countries 100
2. Etiology of Cancer 105
2.1 Identifying Human Carcinogens 106
2.2 Tobacco Smoking 110
2.3 Passive Smoking 118
2.4 Smokeless tobacco 124
2.5 Chronic Infections 128
2.6 alcohol drinking 136
2.7 Reproductive Factors and endogenous Hormones 140
2.8 exogenous Hormones and Cancer 146
2.9 diet, obesity and physical activity 154
2.10 Ionising radiation 160
2.11 Sunlight and Ultraviolet radiation 164
2.12 electromagnetic radiation 170
2.13 occupational exposures 174
2.14 environmental pollution 180
2.15 Genetic Susceptibility 186
3. Mechanisms of Carcinogenesis 189
3.1 Molecular Hallmarks of Cancer 190
3.2 DNA Damage Response and DNA Repair 196
3.3 The Cell Cycle 200
3.4 Cell Death 216
3.5 Invasion and Metastasis 224
3.6 Emerging Technologies 230
3.7 Biomarkers at the Crossroads: Implications for Early Cancer Detection and Diagnosis 236
3.8 Stem Cells and Cancer Stem Cells 240
3.9 Biomarkers and Biological Resource Centres 246
4. Acting for Prevention 261
4.1 Tobacco Control 262
4.2 Prevention of Occupational Cancer 266
4.3 Vaccination 274
4.4 Cancer Chemoprevention 280
4.5 Screening for Cervical Cancer 284
4.6 Screening for Breast Cancer 290
4.7 Screening for Colorectal Cancer 302
4.8 Screening for Oral Cancer 304
4.9 Screening for Stomach Cancer 308
4.10 Screening for Prostate Cancer 310
4.11 Screening for ovarian Cancer 314
4.12 Screening for Lung Cancer 316
4.13 Screening for Cutaneous Malignancies 318
4.14 Genetic Testing 320
5. Cancer Site by Site 329
5.1 Head and Neck Cancers 330
5.2 Esophageal Cancer 338
5.3 Stomach Cancer 344
5.4 Liver Cancer 350
5.5 Pancreas Cancer 358
5.6 GastricBladder Cancer 366
5.7 Colorectal Cancer 374
5.8 Nasopharyngeal Carcinoma 380
5.9 Kaposis Sarcoma 384
5.10 Lung Cancer 390
5.11 Mesothelioma 396
5.12 Non-Melanoma Skin Cancer 398
5.13 Cutaneous Melanoma 404
5.14 Breast Cancer 412
5.15 Cervical Cancer 418
5.16 ovarian Cancer 424
5.17 Endometrial Cancer 428
5.18 Testicular Cancer 432
5.19 Kidney Cancer 438
5.20 Bladder Cancer 444
5.21 Prostate Cancer 450
5.22 Throat Cancer 456
5.23 Tumours of the Nervous System 460
5.24 lymphoma 468
5.25 leukaemia 474
5.26 Cancer in Children 482
5.27 Cancer in Adolescents 488
5.28 Rare Cancers 494
5.29 Cancer in Children 499
Subject index 503
Acknowledgements

It is a great pleasure to acknowledge the enthusiasm of all those who have contributed, directly and indirectly, to the preparation of the World Cancer Report 2008. In addition to the Editors and the Contributors, it is important to acknowledge the great efforts of Sharon Grant (for her assistance with the bibliography), Giorgios Miliotis and Roland Dray (for their assistance with the illustrations) and the staff of Mondolabghi and Natsuprint for their outstanding work on the layout and finalisation of the document.

Caroline Granger and Eric Dell were central figures in the coordination process of this multi-author production, and it is a pleasure to acknowledge Bernard Stewart and Paul Kleihues for their efforts in developing the first World Cancer Report.

Foreword

The International Agency for Research on Cancer (IARC) was founded by Resolution of the World Health Assembly in September 1965. At this time, although data were sparse, cancer was widely considered to be a disease of westernised, high-resource, industrialised countries. Today the situation has changed dramatically, with the majority of the global cancer burden now found in low- and medium-resource countries.

The global burden of cancer has more than doubled during the past 30 years. In 2008, it is estimated that there were over 12 million new cases of cancer diagnosed, 7 million deaths from cancer and 23 million persons alive with cancer. The continued growth and ageing of the world’s population will greatly affect the cancer burden. By 2030, it could be expected that there could be 27 million incident cases of cancer, 17 million cancer deaths annually and 73 million persons alive with cancer within five years of diagnosis.

The greatest impact of this increase will fall on the low- and medium-resource countries. Such countries are, arguably, harder hit by cancer than the high-resource countries. These countries frequently have a limited healthcare budget and a high background level of communicable disease. Cancer treatment facilities are not universally available and life-saving therapies are frequently unavailable for economic reasons. Cancer, and other chronic diseases that are becoming more common, can cause devastating damage to entire families when the head of household and frequently the only source of income for a frequently an extended family, succumbs to cancer.

The rapid increase in the cancer burden represents a crisis for public health and health systems worldwide. A major issue for many countries, even among high-resource countries, will be finding sufficient funds to treat all cancer patients effectively and provide palliative, supportive and terminal care for the large number of cancer patients which will be diagnosed in the coming years.

However, there are prospects for cancer prevention in all resource settings. Tobacco smoking is the best-understood major human carcinogen. One third of cancers in high-resource countries are caused by tobacco smoking, which also causes a large proportion of deaths from other chronic diseases including vascular disease and chronic obstructive pulmonary disease. The worst of the tobacco epidemic has yet to materialise in low-resource countries. There is a 40-year temporal gap between big changes in tobacco prevalence in a population and the peak of the disease epidemic caused by this habit. Tobacco control is a major task for countries irrespective of their resource setting.

Modifiable risk factors for cancer have been identified, including alcohol consumption, excessive exposure to sunlight, lack of physical activity, overweight and obesity, dietary factors, occupational exposures and chronic infection. Effective prevention will reduce the risk of cancer, and effective screening will allow many others to be successfully treated for their disease.

In low-resource countries, many common cancers such as primary liver cancer, cervix cancer, nasopharynx cancer, Kaposi Sarcoma and stomach cancer are caused by chronic infections with different agents. In these circumstances, there are now prospects for prevention via vaccination for hepatitis B (liver cancer) and human papillomavirus (cervix cancer). The major issue in the poorest countries is delivery of the prevention action at a price that is affordable for the countries’ health systems.

Identification of risk factors for cancers is not a simple task, and delivering effective prevention can be even more difficult. Prevention research must take on a higher profile and greater importance in the broad cancer research strategy and in those cancer plans currently being developed. An additional advantage of prevention is that many key risk factors for cancer are shared with other common conditions such as vascular disease and diabetes.

A complete understanding of the mechanisms of the development of cancer is very unlikely to come about in the foreseeable future, making impossible reliance on a single approach to prevent cancer and deaths from the disease. Translational research in its broadest meaning is of paramount importance, covering the spectrum from translating cutting-edge scientific discovery into new approaches to cancer treatment to translating information about cancer risk factors into changes in population behaviour.

Priorities clearly must be identified to tackle the global cancer burden. Such priorities must include a focus on low- and medium-resource countries and the identification, delivery and evaluation of effective cancer control measures. Focus should be on the four pillars of cancer control: prevent those cancers which can be prevented; treat those cancers that can be treated; cure those cancers that can be cured; and provide palliation whenever palliation is required.

Peter Boyle
Director
International Agency for Research on Cancer